+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06778187

Phase 2 Study of Oral Arsenic Trioxide Combined With Low-Intensity Therapy for TP53-Mutated Acute Myeloid Leukemia, Myelodysplastic Neoplasm, and Chronic Myelomonocytic Leukemia

Led by The University of Hong Kong · Updated on 2025-06-10

30

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating oral arsenic trioxide Arsenol 44 combined with ascorbic acid and low-intensity therapies for people with TP53-mutated myeloid malignancies, including acute myeloid leukemia AML, myelodysplastic neoplasm MDS, and chronic myelomonocytic leukemia CMML. This phase 2 open-label study includes patients who are either newly diagnosed or have relapsed or refractory disease after prior treatments. Participants will receive treatment in 28-day cycles. Each cycle includes oral arsenic trioxide given daily from days 1 to 14, along with oral ascorbic acid during the same days. They will also receive one of several low-intensity therapies azacitidine injection or intravenous for 7 days, decitabine intravenous for 5 days, or oral-decitabine-cedazuridine tablets for 5 days. Venetoclax may also be added for 14 days if selected by the investigator. During the study, researchers will monitor participants closely for side effects and treatment responses over 24 months. This includes tracking adverse events, blood and molecular responses, and tolerability of the combination therapy. The study aims to assess safety and effectiveness to inform potential future randomized trials. Participation involves regular visits for treatment, assessments, and laboratory tests throughout the treatment cycles and follow-up periods.

CONDITIONS

Brief Title

Oral-ATO for TP53-mutated Myeloid Malignancies

Research Team

H

Harinder Gill, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here